ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts

robot
Abstract generation in progress

ResMed Inc. (NYSE:RMD) has received an average “Moderate Buy” rating from fourteen analysts, with a consensus twelve-month price target of $299.27. Recent analyst reports show a mix of “overweight,” “buy,” and “hold” ratings, with some price target adjustments. Insider selling by CEO Michael J. Farrell and Director Peter C. Farrell was noted, while institutional investors like Landscape Capital Management and Nordea Investment Management increased their stakes in the company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin